Smartpatient, Novo Nordisk expand digital patient support in Germany

Smartpatient and Novo Nordisk are extending their digital patient support partnership in Germany to cover another obesity therapy form. The move builds on a program launched in 2025 for people with obesity and expanded in early 2026 to type 2 diabetes, signaling broader use of digital care support across therapies.

Why it matters: - The expansion gives people with obesity access to the same digital support program for a new therapy option. - The partnership shows how digital patient support can be adapted across indications and delivery formats without rebuilding the model from scratch. - Novo Nordisk and Smartpatient are using the expanded program to keep patient support consistent as treatment options change.

What happened: - Smartpatient and Novo Nordisk expanded their partnership in Germany on Sept. 2, 2026. - The existing digital companion program for obesity now includes an additional therapy form. - The collaboration began in 2025 with a joint digital support program for people with obesity in Germany. - The program was extended in early 2026 to people with type 2 diabetes.

The details: - Smartpatient said the latest extension broadens an established obesity support program to different dosage forms. - Marcelo Duhalde, Chief Growth Officer at Smartpatient, said the expansion shows how a patient support partnership can grow with changing treatment needs. - Duhalde said the goal is a continuous and consistent patient experience. - Claudia Laven, Head of Obesity at Novo Nordisk Deutschland, said new innovations created a need for new support solutions. - Laven said the expanded partnership builds on an established digital program for obesity while reflecting further therapy development. - Laven said consistent support across both dosage forms is an important part of patient support in Germany.

Between the lines: - The agreement suggests pharma companies can extend one digital support framework across multiple indications instead of launching separate programs for each therapy. - Smartpatient is positioning the model as a scalable patient engagement tool for treatment persistence and real-world insights. - Novo Nordisk is framing digital support as part of the patient experience, not just an add-on to drug access.

What's next: - The expanded obesity support program is now available for the new therapy option in Germany. - Smartpatient and Novo Nordisk appear set to continue adapting the program as therapy formats and patient needs evolve. - The partnership could serve as a template for adding future indications or support features over time.

The bottom line: - Smartpatient and Novo Nordisk are turning one digital patient support program into a broader multi-therapy model for Germany.